Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Mark Jesus M MagbanuaOleksandr SavenkovErik J AsmusKarla V BallmanJanet H ScottJohn W ParkMaura DicklerAnn PartridgeLisa Anne CareyEric P WinerHope S RugoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
CTCs were highly prognostic for the addition of bevacizumab to first-line letrozole in patients with HR+ MBC in CALGB 40503. Further research to determine the potential predictive value of CTCs in this setting is warranted.